Gastric cancer (GC) is one of the most common malignancies worldwide. Most patients are
diagnosed at advanced stages due to the subtle symptoms of earlier disease and the low …

Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …

Despite success in hematologic malignancies, the treatment landscape of chimeric antigen
receptor (CAR) T cell therapy for solid tumors remains limited. Claudin18. 2 (CLDN18. 2) …

Background The additive or synergistic sustained antitumour effect of immune checkpoint
inhibitors in combination with oxaliplatin-based chemotherapy has previously been …

Background First-line chemotherapy for advanced or metastatic human epidermal growth
factor receptor 2 (HER2)-negative gastric or gastro-oesophageal junction adenocarcinoma …

Despite neoadjuvant/conversion chemotherapy, the prognosis of cT4a/bN+ gastric cancer is
poor. Immune checkpoint inhibitors (ICIs) and antiangiogenic agents have shown activity in …

Gastric cancer remains a major unmet clinical problem with over 1 million new cases
worldwide. It is the fourth most commonly occurring cancer in men and the seventh most …

Gastric cancer (GC) is one of the most malignant human cancers with increasing incidence
worldwide, ranking among the top five malignant tumors worldwide in terms of incidence …

Background No adjuvant treatment has been established for patients who remain at high
risk for recurrence after neoadjuvant chemoradiotherapy and surgery for esophageal or …

Gastric cancer is one of the most common cancers in Korea and the world. Since 2004, this
is the 4th gastric cancer guideline published in Korea which is the revised version of …